{"changeSha256":"c602dfa14fcb26d421a2b842ef533d38be10823d47f4afb8f37a1f4542913b7c","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.","before":"An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.","field":"Profile summary"},{"after":"The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.","before":"ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.","field":"Evidence note"},{"after":"ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d","before":"ctg-nct07589686-v3","field":"Cited source records"},{"after":"Hoffmann-La Roche [sources: ctg-nct07589686-v3]; Zealand Pharma [sources: ctg-observation-nct06662539-2026-03-23-25a9d8533efb]","before":"Hoffmann-La Roche [sources: ctg-nct07589686-v3]","field":"Named organizations"},{"after":"name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b","before":"name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3; summary: ctg-nct07589686-v3; evidenceNote: ctg-nct07589686-v3","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/petrelintide/versions/3/","version":3},"id":"profile:petrelintide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials.","peptideSlugs":["petrelintide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/petrelintide/v2.json","sha256":"27174994a9b3f091c1afcb519cb83a4a5efaa054522be9ec476fc84d105ab32f"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/petrelintide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-42017294","name":"Diabetes, Obesity and Metabolism","sourceClass":"A","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294","url":"https://doi.org/10.1111/dom.70753","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697","url":"https://clinicaltrials.gov/study/NCT07843472","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct07843485-2026-11-05-e5fd0540362d","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5","url":"https://clinicaltrials.gov/study/NCT07843485","verifiedAt":"2026-11-14"}],"subject":{"slug":"petrelintide","type":"profile"}}
